Immunization

The pilot Will Evaluate Measure Concepts and Data Exchange in Value-Based Arrangements.

Investigators suggested that the future cost-effectiveness of respiratory syncytial virus (RSV) vaccination could be improved through lower vaccine prices and longer-lasting protection.

Researchers addressed the association between older individuals who received an influenza vaccine and their risk of stroke following vaccination.

The National Foundation for Infectious Diseases released a survey regarding the feelings of US adults toward influenza, COVID-19, RSV, and pneumococcal disease.

Researchers aimed to address how community pharmacies target vulnerable groups regarding the promotion of vaccinations.

Catch up on important immunization news from the month of September.

The vaccine will be made available via third-party online pharmacies.

A co-administration option for both vaccinations can increase the likelihood of older adults completing the vaccination series and improve health outcomes for the patient population.

The MVA-BN vaccine is manufactured by Bavarian Nordic and has shown strong efficacy against mpox infection in real-world studies.

Industry experts and physicians conducted a state-by-state breakdown of vaccination statistics for children and teenagers as well as adults and elderly individuals.

Researchers explored an alternative pharmacist education intervention as a way of improving pharmacist-patient conversations and decreasing vaccine hesitancy among patients.

The vaccine, VAX-31, targets 20 serotypes in common with PCV20, as well as 11 additional serotypes.

The protein-based vaccine includes a monovalent component corresponding to the Omicron variant JN.1 strain.

Catch up on important immunization news from the month of August.

Chijioke Bennett, executive director of clinical development at Novavax, discusses how health care providers can increase awareness around the importance of COVID-19 vaccines.

Emergent BioSolutions has announced that it will donate 50,000 doses of ACAM2000 for potential deployment across affected areas in Central Africa.

“While seasonal variation exists, it is expected that seniors will continue to benefit from flu vaccines that are stronger than the traditional standard-dose vaccines,” wrote investigators.

Novavax is still awaiting FDA authorization for their protein-based COVID-19 vaccine.

Access inequities are preventing the US-affiliated Pacific Island (USAPI) jurisdictions from meeting the WHO 2030 goal of 90% human papillomavirus (HPV) vaccination series completion coverage.

A CDC report called for “increased efforts” to ensure parents can obtain all recommended vaccines for their eligible children and realize the full potential of the VFC program.

TAK-003 could be a powerful combatant against the increasing global threat of dengue virus.

The composition of the latest flu vaccine has changed. Here’s what pharmacists need to know.

The technology from Diakonos Oncology initiates a natural immune response that targets and eliminates cancer cells by activating cytotoxic TH1 cell signaling pathways.

Catch up on important immunization news from the month of July.

MK-1654 (clesrovimab) met its primary efficacy endpoint of incidence of patients with RSV-associated medically attended lower respiratory infections (MALRI) through Day 150.

All participants in the phase 3 clinical trial have completed their primary vaccination series.

“If people think COVID is no big deal and decide to forgo vaccinations, they’re essentially doubling their risk of developing long COVID,” wrote investigators.

Updated vaccines are expected to be available in the coming months.

Global coverage for diphtheria, tetanus, and pertussis has reached its lowest point in 15 years.

Researchers are evaluating the safety, tolerability, and immunogenicity of shingles vaccine candidate Z-1018.